Objectives:
Human and animal tissues contain material that (a) cross-reacts with antibodies raised against cardiac glycosides, (b) stimulates natriuresis, and (c) inhibits Na+,K+-ATPase activity; that is, endogenous digitalis-like factors (EDLF) (for review see [1, 2] ). Plasma levels of EDLF have been found to be increased in hypertension in humans and laboratory animals [3-51. It has been hypothesized that EDLF is released in order to promote natriuresis in plasma volume-dependent forms of hyperteniion [6, 7] . However, EDLF may also inhibit Na+,K+-pump in vascular smooth muscle membrane, thereby enhancing vasoconstriction [6, 7] . Experimental volume-dependent hypertension [8, 9] Ouabain that have a bufodienolide (rather than cardenolide, Fig. 1 ) structure [16] . Pharmacological effects of various bufodienohdes have been analyzed in a number of studies, and various bufodienolides have been found to be potent Na+,K+-ATPase inhibitors and positive inotropic agents (for review see [17] ). Two bufodienolides, bufalin and resibufagenin, were shown to be vasoconstrictors [18, 19] . Recently, the venom of Bufo marinus toad was found to contain digoxin-like immunoreactive material that is distinct from bufalin and resibufagenin [20] . This material causes rapid and sustained vasoconstriction in rat aorta, evokes positive inotropic effects in vitro, and inhibits Na+,K+-ATPase [20] . One of the major constituents of Bufo murinus venom, marinobufagenin ', has been found recently to be responsible for the observed vasoconstrictor effects [21] .
Several recent findings suggest that mammals, as well as amphibia, have a bufodienolide EDLF. First, Kieval et al. 1221 found bufalin-like immunoreactive material in extracts of human bile. Naomi et al. [23] analyzed the apparent levels of digitalis-like factors in human serum using various digoxin antibodies, and suggested that human digoxin-like immunoreactive factor demonstrates substantial immunological similarity to bufalin. Lichtstein et al. mass-spectrometrically detected the presence of bufalin and its derivatives in human eye lenses [24] . Plasma from humans and rats has been shown to contain a material ' which cross-reacts with antibodies raised against the bufodienolides, proscillaridin [25] and marinobufagenin 1261.
The present study was conducted to determine whether plasma volume expansion via rapid saline infusion increases plasma concentrations and urinary release of endogenous marinobufagenin-like, as well as ouabain-like, immunoreactive material in anesthetized dogs. The possible role of EDLF in the cardiovascular and natriuretic responses to plasma volume expansion was investigated by pretreatment with an antidigoxin antibody, which had been shown previously to cross-react with Na+,K+-ATPase inhibitory material from the venom of Bufo murinus toads [20, 21] .
Methods
The experiments were conducted with 14 male mongrel dogs (lo-16 kg, Haycock Kennels, Quakertown, PA) which were deprived of water and food for 24 h preceding the experiment. Following an initial injection of pentobarbital sodium (17 mg . kg -' IV), anesthesia was maintained for the duration of the experiment via intravenous infusion of 0.5% biotal (Thiamylal sodium, Bio-Sivtic Co.). The dogs were artifically ventilated (Ohmeda model 7000, Denver, CO> with a mixture of 50% 0, and room air via an intratracheal tube. The right femoral vein and left femoral artery were carmulated with polyvinyl chloride tubing for saline infusion and continuous recording of blood pressure (Beckman p10 minitransducer), respectively. A catheter was placed in the left carotid artery and advanced to the left ventricle for measurement of intraventricular pressure via a pressure transducer (model Statham P23 Db, Gould-Statham, Oxnard, CA), and its first derivative, LVd P/d t (Beckman strain gauge and d P/d t coupler, connected to a Beckman polygraph). The right cephalic vein was catheterized for blood collection. A Foley catheter was placed in the urinary bladder for urine collection.
Saline diuresis was induced as reported previously [27] by intravenous infusion of isotonic saline (i.e. 0.9% sodium chloride) via a peristaltic pump (Harvard, model 607, Harvard Apparatus Co, Milles, MA). Five hundred ml saline were infused during the first 30 min to initiate diuresis (17 ml/min), followed by a 2-h infusion at a rate of 10 ml/min and 1200 ml to maintain it. Urine was collected every 15 min, filtered through 0.45 km Mill&ore filters and stored at -20°C for measurement of Na+, K+, ouabain-like and marinobufagenin-like immunoreactivity. Venous blood samples (2 ml) were collected in heparinized tubes every 5 min during the first 30 min of saline infusion and every 30 min thereafter. Hematocrit was measured at the same times. After centrifugation, plasma was stored at -20°C for measurements of Naf, K+ (Beckman E2A analyzer), digoxin-like, ouabain-like and marinobufagenin-like immunoreactivity.
For immunoas- 
says (except DELFIA digoxin assay), the plasma proteins were precipitated by treatment of plasma with 3.3% trichloracetic acid, as previously reported in detail [28] . The experimental design consisted of three groups: nontreated, which received saline infusion only (n = 5), dogs pretreated with rabbit antidigoxin antibody (50 pg . kg-', Sigma Chemicals, St. Louis, MO) 60 min prior to commencing the saline infusion (n = 51, and dogs which received rabbit antimouse (control) antibody (50 pg * kg-' , Sigma Chemicals, St. Louis, MO) 60 min prior to commencing the saline infusion (n = 4). Digoxin antibody was given to antagonize the effects of EDLF, while rabbit antimouse antibody was used in order to demonstrate that the effects of the digoxin antibody were not due to nonspecific reactions, such as complement activation.
Ouabain-like immunoreactivity in protein-free plasma and in nonextracted urine was measured using a modified New England Nuclear ouabain ELISA kit, based on the competition between immobilized ouabain conjugate and sample ouabain for rabbit antiouabain antibody. Then, the bound rabbit antibody was detected using labelled secondary antibody (europium-labelled goat antirabbit antibody, Wallac OY, Turku, Finland). Interactions of ouabain, digoxin and marinobufagenin with antiouabain antibody from the immunoassay are presented in Fig. 1A and in Table 1 . The sensitivity of ouabain assay was 0.01 nmol . 1-l.
Marinobufagenin-like immunoreactivity was analyzed in protein-free plasma and in nonextracted urine using a solid-phase fluoroimmunoassay. The method is based on a competition between the immobilized conjugate (marinobufagenin-3-gl ycoside-RNAase, 19: 1) and a sample of EDLF for rabbit polyclonal antimarinobufagenin antibody. Marinobufagenin was separated from the venom in parotid glands of Bufo marinus toads using thin layer chromatography, as reported previously [29, 30] with minor modifications [21] . Marinobufagenin-3-glycoside was synthesized, as described by Koenigs and Knorr [31] , with some modifications [32] . Marinobufagenin-3-glycoside-BSA and marinobufagenin-3-glycoside-RNAase conjugates were prepared, and rabbits were immunized with marinobufagenin-3-glycoside-BSA, as previously reported by Curd et al. [33] for digoxin. The mixture of immunoglobulins was separated from the serum using caprylic acid [34] . Marinobufagenin-3-glycoside-RNAase conjugate (1 .O pg of conjugate in 100 ~1 of phosphate-buffered saline per well) was immobilized on the bottom of NUNC microtitration strip wells as reported in detail previously [35] . We added 40 ~1 of marinobufagenin standards and unknown samples to the coated wells, followed by 100 ~1 of marinobufagenin antibody.
After 1 h incubation, the strips were washed twice (DELFIA wash solution, Wallac OY, Turku, Finland), following which 100 ~1 of secondary antibody was added (europium-labelled goat anti-rabbit antibody, Wallac OY, Turku, Finland). After 1 h incubation, the wells were washed six times with the wash solution. Then, 200 ~1 of enhancement solution, which releases the europium conjugated with the secondary antibody, (Wallac OY, Turku, Finland) was added into each well, the strips were shaken for 5 min, and after 10 min more the fluorescence of free europium was measured (DELFIA 1234 Arcus Fluorometer, Wallac OY, Turku, Finland). The sensitivity of the immunoassay was 0.001 nmol * 1-l. The interactions of antimarinobufagenin antibody with marinobufagenin, ouabain and digoxin are presented in Fig. IB . The results demonstrating cross-reactivity of antimarinobufagenin antibody with various substances are presented in Table 1 .
Digoxin-like immunoreactivity was measured in duplicate in crude plasma of the dogs pretreated with digoxin antibody using a commercial kit (DELFIA 1244011 Digoxin immunoassay, LKB Wallac, Finland) and expressed as apparent ng . ml-' of digoxin equivalents. DELFIA is a solid-phase immunoassay based on a competition between the immobilized digoxin and sample digoxin (or EDLF) for europium-labelled affinity purified rabbit polyclonal antidigoxin antibody. The interassay reproducibility of the method was 5.5%. The sensitivity of the method was 0.1 ng eml-' of digoxin equivalents. The cross-immunoreactivity values of antidigoxin antibody The cross-immunoreactivity of antidigoxin antibody used for pretreatment of the dogs was evaluated by solidphase immunoassay. The method was the same as described for the marinobufagenin immunoassay. For coating, the microtitration strips were incubated with 0.25 kg/well of digoxin-BSA conjugate. The titer of digoxin antibody used for the plotting of calibration curves was 1: 12000. The data on cross-reactivity of pretreatment digoxin antibody are presented in Table 1 . The interactions of the pretreatment antidigoxin antibody with digoxin, marinobufagenin and ouabain are presented in Fig. 1C .
The cross-immunoreactivity of the assays (Table 1 ) was expressed as the ratio of the amount of cross-reactant required to displace 50% of antimarinobufagin, antiouabain or antidigoxin antibody from immobilized conjugate, to the amount of the cross-reactant to give the same 50% displacement.
The results were evaluated statistically using two-tailed paired (within group comparisons over time between each normally-distributed parameter) and unpaired (comparisons between groups) r-tests, and two-tailed paired Wilcoxon test (within-group comparisons for nonrandomly distributed data). The results were considered statistically significant if the analyses of the differences between the means of the parameters analyzed had a value of P less than 0.05. Fig. 2A shows that mean hematocrit of each group decreased during the first 30 min of saline infusion. The decreased levels were maintained for the duration of the experiments and did not vary between experimental groups.
Results

Hemodynamic efsects
Pretreatment with control (rabbit antimouse) antiserum 60 min before plasma volume expansion resulted in no significant changes in any of the parameters studied. At the same time, pretreatment with antidigoxin antibody caused a small short-lasting (15-20 min) but significant decrease in mean blood pressure (170.1 f 2.6 vs. 158.7 f 2.0; P < 0.01) and a parallel 10% decrease in cardiac contractility. This decrease in cardiovascular performance was associated with a parallel decrease in the levels of digoxin-like immunoreactivity in nonextracted plasma (DELFIA immunoassay, 0.076 f 0.023 vs. 0.036 f 0.011 ng . ml-' of digoxin equivalents, P < 0.05). By the time that saline infusion was initiated, however, neither mean blood pressure nor cardiac contractility of the animals pretreated with digoxin antibody were significantly different from those of the nontreated dogs or those pretreated with rabbit antimouse antibody (Fig. 2C and D) .
As shown in Fig. 2B , a rapid 25% increase in LVd P/dt was observed during the first 10 min of saline infusion in the nontreated dogs and in those pretreated with rabbit antimouse antibody. At the same time, cardiac contractility did not increase in volume-expanded dogs pretreated with antidigoxin antibody. As presented in Fig. 2C and D, plasma volume expansion was associated with no consistent changes in mean blood pressure or heart rate in any experimental group. As shown in Table 2 , plasma concentrations of Na did not change during the experiment, while plasma K was decreased during 30-90 min in all groups. Plasma concentrations of Na and K in dogs pretreated with rabbit antimouse antibody did not differ from the values in the nontreated dogs (Table 2 ).
Diuresis and urinary electrolytes
As shown in Table 3 , no differences in urine volume or urinary output of Na and K were observed between nontreated dogs and animals pretreated with the control (rabbit antimouse) antibody. However, the mean output of urine, as well as urinary output of Na and K, in antidigoxin antibody pretreated dogs was significantly lower than in the other two groups.
Digitalis-like factors
Mean baseline plasma concentration of marinobufagenin-like immunoreactive material in nontreated dogs was 0.30 f 0.16 nmol -1-l (Fig. 3A) . Plasma levels of marinobufagenin-like immunoreactivity increased (11.87 f 3.16 nmo1*1-', P < 0.01) within 10 min of saline infusion, decreased within 25 min (2.21 f 0.59 nmol * l-' >, and then showed a second increase (11.8 f 2.8 nmol . l-', P < 0.01) (Fig. 3A) .
Before the onset of saline infusion, mean plasma concentration of ouabain-like immunoreactive material for the nontreated dogs was 0.019 f 0.004 nmol * 1-r (Fig. 3B) . As also shown in Fig. 3B , a small but consistent increase in plasma ouabain-like immunoreactivity was observed in all five dogs 25 min following saline infusion (0.139 f 0.056 vs. 0.019 f 0.004 nmol * 1-r; P < 0.05). After 90- The (min) (Fig. 3B) .
As presented in Fig. 4A , in untreated volume-expanded dogs the maximal urinary output of marinobufagenin-like immunoreactive material was observed during the first 30 min of saline infusion (5763 f 1123 150 min, the release of marinobufagenin-like immunoreactive material gradually decreased by approximately 80% (667 f 221 pmol during 150-180 min of volume expansion). Urinary excretion of ouabain-like immunoreactive material showed a time course similar to that of marinobufagenin-like immunoreactive material (Fig. 4B) .
As presented in Fig. 4A , in volume-expanded dogs pretreated with antidigoxin antibody, there was a significant decrease in urinary release of marinobufagenin-like immunoreactive material. By contrast, urinary excretion of ouabain-like material in these antidigoxin antibody pretreated animals did not differ from the values obtained from the nontreated volume-expanded dogs (Fig. 4B) .
Discussion
As in previous reports, the present study showed that acute plasma volume expansion of anesthetized dogs stimulates EDLF [27, 36, 37] . The major observation of the present study is the finding that acute saline plasma expansion caused an increase in plasma levels of an endogenous marinobufagenin-like immunoreactive material and stimulated its urinary output. These results provide further evidence that, like amphibia, mammals have endogenous Na,K-pump inhibitors of a bufodienolide nature.
The values of blood pressure, heart rate and cardiac contractility in our study were comparable to those reported in previous studies with anesthetized dogs [38, 39] . Levels of urine volume, Na and K excretion, and changes in hematocrit were also similar to those observed during plasma volume expansion in anesthetized dogs [27] . In the present study, no increases in blood pressure were observed in response to the saline infusion procedure. The first 30 min of plasma volume expansion were associated with a 25% increase in cardiac contractility. These observations are consistent with the results of previous studies showing that a comparable rate of saline infusion increased cardiac output within 30 min and total peripheral resistance only after 1 h or more [40] . In the present study, animals were anesthetized with pentobarbitone sodium, which increases blood pressure [38] . In previous experiments on isolated arteries from rats [21] and dogs [41] , marinobufagenin acted as a vasoconstrictor. The pressor response of the anesthetic might have masked the expected pressor effects of increased plasma levels of the marinobufagenin-like immunoreactive substance.
Administration of the control (rabbit antimouse) antibody did not prevent any of the effects of the plasma volume expansion. Therefore, the effects of antidigoxin antibody are unlikely to be of a nonspecific nature (e.g. complement activation, which may have circulatory effects) [ 111.
Plasma concentrations of marinobufagenin-like immunoreactivity increased by almost 40 times during the first 15 min of saline infusion, when cardiac contractility was maximal. This observation is in accord with previous studies showing that bufodienolides exert positive inotropic effects [ 17,391. In parallel with the positive inotropic response to saline infusion, we observed a decrease in plasma potassium concentration. This decrease, which may have contributed to the inhibition of the sodium pump, could have accounted for the observed positive inotropic response. However, the finding that antidigoxin antibody pretreatment prevented the increase in cardiac contractility suggests that the increase during saline infusion was more likely to be due to the effect of circulating substance(s) with digoxin-like immunoreactivity.
Recently, it was shown that the inotropic, as well as vasoconstrictor and Na,K-ATPase inhibitory effects of EDLF from Bufo nwinus toad venom, are all antagonized by polyclonal antidigoxin antibody [20,2 11 .
The initial increase in plasma levels of marinobufagenin-like immunoreactivity occurred during the first 10 min of saline infusion. A second increase in plasma levels of marinobufagenin-like immunoreactivity was observed after 60 min of saline infusion, in parallel with the maximal diuretic and natriuretic responses. This two-phase increase in plasma EDLF could reflect the two phases of intravenous saline infusion. At the same time, the maximal This dissociation between the plasma and urinary profiles of marinobufagenin-like immunoreactivity might be a consequence of the fact that a large portion of marinobufagenin was bound to plasma proteins. Thus, the baseline levels of marinobufagenin-like immunoreactivity in protein-free plasma in the present study were in the nanomolar range of concentrations. When we analyzed the crude plasma [42] , the baseline levels of marinobufagenin-like immunoreactivity were significantly higher, up to 200 mnol . 1-l. This observation suggests that plasma proteins may interfere with the immunoassay and/or that a large portion of the compound exists in the protein-bound form. Of course, only the compound which is not bound to proteins could be excreted by the kidneys. Although the effect of massive saline infusion on protein binding of the steroids is unknown, one could hypothesize that an increase in plasma concentration of protein-bound steroid occurring in parallel with a decrease in the levels of unbound substance might have resulted in a dissociation between plasma concentrations and urinary output of EDLF.
In addition, urinary release is not the only mechanism of steroid degradation: following systemic administration to mammals, a large proportion of steroids are metabolized in the liver [43, 44] . Therefore, the dissociation between urinary and plasma profiles of marinobufagenin-like immunoreactivity during acute volume expansion may also be connected with a changing capacity of the liver to metabolize these compounds.
Pretreatment of the dogs with antidigoxin antibody prevented the increase in cardiac contractility during plasma volume expansion. In addition, antidigoxin antibody pretreatment attenuated the diuresis and the urinary release of Na and K caused by the expansion of plasma volume. Therefore, an EDLF which cross-reacts with antidigoxin antibody also appears to be involved in the development of volume expansion natriuresis.
Levels of marinobufagenin-like immunoreactivity in plasma from antidigoxin antibody-pretreated volume-expanded dogs were not measured in the present study. As indicated above, concentrations of marinobufagenin-like immunoreactive material in crude plasma were extremely high, which strongly indicated interference in the assay by plasma proteins. On the other hand, measurement of EDLF in protein-free plasma from the antibody-pretreated dogs might be misleading, because the pretreatment antibody would sediment together with plasma proteins. There is a substantial body of evidence demonstrating the difficulties of measuring the ligand in plasma after in vivo administration of the antibody to this ligand [45, 46] .
Plasma concentrations of ouabain-like immunoreactivity in the present study were comparable with levels reported previously by Gottlieb et al. in human plasma [47] . As compared with marinobufagenin-like immunoreactive substance, plasma ouabain-like immunoreactivity showed smaller increases during the first 30 min of saline infusion, but greater increases after 90 min of saline infusion.
Recently, it has been suggested that the ouabain-like immunoreactive factor measured by immunoassay does not have the same retention time as authentic ouabain and that plasma levels of endogenous ouabain (such as observed in these experiments) are too low to produce functionally significant inhibition of the sodium pump [4&49]. However, endogenous ouabain-like immunoreactive factor may represent not ouabain itself but its stereoisomer which could react with ouabain antibody [SO] . Different isoforms of Na,K-ATPase (which are likely to impart differential sensitivity to the sodium pump with regard to the effects of various inhibitors) are distributed in mammalian tissues in a nonhomogenous fashion. Human brain and heart Na,KATPase may be inhibited by digitoxigenin and bufalin derivatives at concentrations as low as 0.1 and 0.01 nmol . l-' , respectively [5 11. Recent observations demonstrated the presence of the highly ouabain-sensitive alpha-2 and alpha-3 isoforms of Na,K-ATPase in mammalian vascular tissue [52, 53] . Na,K-ATPase from central nervous structures also contains o-2 and (r-3 isoforms [54] . The involvement of the central nervous system in the cardiovascular effects of EDLF has also been demonstrated [55] .
Pretreatment with the antidigoxin antibody decreased urinary excretion of marinobufagenin-like immunoreactive material (Fig. 4A) . At the same time, antidigoxin antibody administration did not affect the urinary release of ouabain-like immunoreactive material (Fig. 4B) . This observation suggests that the antidigoxin antibody interacts with a bufodienolide EDLF rather than with endogenous ouabain. Comparison of the interactions of digoxin, ouabain and marinobufagenin with the antidigoxin antibody supports this view (Fig. 1) . For example, in the digoxin immunoassay, marinobufagenin demonstrated 50 times higher cross-immunoreactivity with antidigoxin antibody than ouabain. In the ouabain immunoassay, both digoxin and marinobufagenin were more similar to each other than to ouabain. Finally, in the marinobufagenin immunoassay, ouabain demonstrated very low marinobufagenin-like immunoreactvity (less than 0.004%).
Previously, antidigoxin antibodies have been used to measure concentrations of EDLF [ 14, 15, 56] and to antagonize the effects of EDLF in vivo [ 11,121. However, the results of the studies using digoxin antibodies for measurement of plasma levels of EDLF are controversial, because different digoxin antibodies demonstrate wide variability in their ability to detect EDLF, due perhaps to interactions with other circulating substances [1, 57] . Naomi et al. [23] , using several digoxin antisera and several substances which were potential EDLF, established immunological profiles of plasma EDLF from different groups of patients, and suggested that a circulating digoxin-like substance may have a bufodienolide nature. The results of the present experiment support that suggestion. Further studies are needed to determine the chemical structure of the endogenous marinobufagenin-like immunoreactive substance.
